A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Avipendekin pegol (Primary) ; Cetuximab (Primary)
- Indications Anal cancer; Carcinoma; Cervical cancer; Colorectal cancer; Cutaneous B-cell lymphoma; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nektar Therapeutics
- 04 Feb 2024 This trial has been discontinued in Italy.
- 15 May 2023 Status changed from active, no longer recruiting to completed.
- 16 Mar 2023 Status changed from recruiting to active, no longer recruiting.